A Study To Determine The Effect Of SB-480848 On Asthma

Male and female subjects who have documented persistent asthma for at least 3 months

• Subjects must have been on a stable, low-dose ICS for a minimum of 4 weeks prior to the screening visit.
• Aged 18-65 years, at screening
• FEV1 greater than or equal to 70% predicted (ECCS, 1993)
• Subjects must show an increase in FEV1 greater than or equal to 12% (and an absolute change >200mL) within 30 minutes following inhalation of 4 puffs of albuterol/salbutamol or 1 nebulized treatment of 2.5mg or have historical, documented evidence of reversibility, within 12 months prior to screening
• Subjects must be willing to replace their inhaled, short-acting β2-agonist with study provided albuterol/salbutamol
• Patient must be capable of giving informed consent and comply with the study requirements and timetable. Inclusion Criteria following run in period (Prior to randomisation) Subjects will be screened based on the inclusion and exclusion criteria noted above. During the run-in period [Day -14 to Day 1], subjects will be asked to maintain a diary card and document the number of puffs of rescue inhaled, short-acting β2-agonists taken, asthma-related symptoms and night time awakenings as well as morning and evening PEF measurements. On the morning of Day 0, subjects will be eligible for randomisation into the study if all of the following criteria are met:

The patient has life threatening asthma. A research patient must not have been hospitalized two or more times in the last year prior to Day 0 due to asthma and must not have been hospitalized within 6 months prior to Day 0

• Subjects with daily asthma-related symptoms.
• Subjects taking any of the medications listed in the protocol for the listed interval prior to the screening visit or during the study:
• Subjects with historical or current evidence of any other disease.
• Subjects with clinically significant abnormal findings on physical exam or other screening procedures.
• Subjects who have received an investigational product within 30 days or 5 half-lives [whichever is longer] prior to the first dose of study medication
• Subjects who have tested positive for hepatitis C antibody, hepatitis B surface antigen or HIV.
• Subjects with history of drug or alcohol abuse
• Positive drug (not related to known medications the subject is taking at time of screening), alcohol or cotinine/carbon monoxide (CO) test at screening or at Day 0
• Subjects with a history of regularly drinking more than 2 (females)/3 (males) units of alcohol a day.
• Pregnant or nursing female subjects.
• Female subjects of childbearing potential with an unwillingness to agree to one of the methods of contraception listed in the protocol.
• Subjects who suffer from any medical condition which in the opinion of the investigator would compromise patient safety or ability to comply with study procedures
• Subjects who are current smokers or have given up smoking within the previous six months or who have a smoking history > 10 pack years.
• Subjects with history of an upper or lower respiratory tract infection or symptoms (including the common cold) within 2 weeks prior to first dose of study medication
• Subjects who have donated more than 500ml of blood within 56 days prior to the first dose of study medication
• Subjects who are currently receiving potent 3A4 inhibitors be excluded.
• Subjects on β-adrenergic receptor blockers within 3 months prior to screening visit
• Subjects previously hospitalized as a result of a methacholine challenge